These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 38149471

  • 1. Characteristics and outcome of systemic treatment for metastatic or unresectable thymic carcinoma: A single institution experience.
    Ho IW, Pan YL, Lai JI, Liu CY.
    Thorac Cancer; 2024 Feb; 15(4):339-346. PubMed ID: 38149471
    [Abstract] [Full Text] [Related]

  • 2. Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimens.
    Ma WL, Lin CC, Hsu FM, Lee JM, Chen JS, Huang YL, Chang YL, Chang CH, Yang JC.
    Cancer Med; 2022 Sep; 11(18):3445-3456. PubMed ID: 35348307
    [Abstract] [Full Text] [Related]

  • 3. Second-line treatment options in advanced thymic carcinoma after failure of platinum-based chemotherapy: A multicenter retrospective study.
    Wang Y, Zhang X, Tian D, Han S, Zhang J, Nie J, Dai L, Hu W, Chen X, Ma X, Tian G, Wu D, Zhang Z, Long J, Fang J.
    Cancer Med; 2023 Feb; 12(3):2303-2311. PubMed ID: 35924403
    [Abstract] [Full Text] [Related]

  • 4. Optimal first-line treatment for advanced thymic carcinoma.
    Yang X, Zhuo M, Shi A, Yang S, Wang Z, Wu M, An T, Wang Y, Li J, Zhong J, Chen H, Jia B, Dong Z, Zhao J.
    Thorac Cancer; 2019 Nov; 10(11):2081-2087. PubMed ID: 31574576
    [Abstract] [Full Text] [Related]

  • 5. Systemic treatments for thymoma and thymic carcinoma: A systematic review.
    Berghmans T, Durieux V, Holbrechts S, Jungels C, Lafitte JJ, Meert AP, Moretti L, Ocak S, Roelandts M, Girard N.
    Lung Cancer; 2018 Dec; 126():25-31. PubMed ID: 30527189
    [Abstract] [Full Text] [Related]

  • 6. Comparison of Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy between B3 Thymoma and Thymic Carcinoma.
    Hao Y, Si J, Jin J, Wei J, Xiang J, Xu C, Song Z.
    Curr Oncol; 2022 Dec 02; 29(12):9452-9460. PubMed ID: 36547157
    [Abstract] [Full Text] [Related]

  • 7. Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma.
    Hirai F, Seto T, Yamanaka T, Toyozawa R, Inamasu E, Kojo M, Toyokawa G, Morodomi Y, Shiraishi Y, Takenaka T, Yamaguchi M, Takenoyama M, Ichinose Y.
    Jpn J Clin Oncol; 2013 Oct 02; 43(10):1018-22. PubMed ID: 23917962
    [Abstract] [Full Text] [Related]

  • 8. Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203.
    Tsukita Y, Inoue A, Sugawara S, Kuyama S, Nakagawa T, Harada D, Tanaka H, Watanabe K, Mori Y, Harada T, Hino T, Fujii M, Ichinose M.
    Lung Cancer; 2020 Jan 02; 139():89-93. PubMed ID: 31751805
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma.
    Wang Y, Nie J, Dai L, Hu W, Chen X, Han J, Ma X, Tian G, Han S, Long J, Zhang Z, Fang J.
    Thorac Cancer; 2019 Jan 02; 10(1):17-23. PubMed ID: 30411854
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Results of S-1-based chemotherapy for platinum (and antrathycline)-refractory advanced thymic carcinoma.
    Hirai F, Seto T, Inamasu E, Toyokawa G, Yoshida T, Nosaki K, Takenaka T, Yamaguchi M, Takenoyama M, Ichinose Y.
    Anticancer Res; 2014 Oct 02; 34(10):5743-7. PubMed ID: 25275083
    [Abstract] [Full Text] [Related]

  • 12. Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study.
    Tateishi K, Ko R, Shukuya T, Okuma Y, Watanabe S, Kuyama S, Murase K, Tsukita Y, Ashinuma H, Nakagawa T, Uematsu K, Nakao M, Mori Y, Kaira K, Mouri A, Miyabayashi T, Sakashita H, Matsumoto Y, Tanigawa T, Koizumi T, Morita S, Kobayashi K, Nukiwa T, Takahashi K, North East Japan Study Group.
    Oncologist; 2020 Apr 02; 25(4):e668-e674. PubMed ID: 31771990
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity.
    Okuma Y, Hosomi Y, Takagi Y, Iguchi M, Okamura T, Shibuya M.
    Lung Cancer; 2011 Dec 02; 74(3):492-6. PubMed ID: 21665316
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Phase II study of Amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan Lung Cancer group study 0803.
    Inoue A, Sugawara S, Harada M, Kobayashi K, Kozuki T, Kuyama S, Maemondo M, Asahina H, Hisamoto A, Nakagawa T, Hotta K, Nukiwa T.
    J Thorac Oncol; 2014 Dec 02; 9(12):1805-9. PubMed ID: 25393793
    [Abstract] [Full Text] [Related]

  • 17. Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study.
    Ko R, Shukuya T, Okuma Y, Tateishi K, Imai H, Iwasawa S, Miyauchi E, Fujiwara A, Sugiyama T, Azuma K, Muraki K, Yamasaki M, Tanaka H, Takashima Y, Soda S, Ishimoto O, Koyama N, Morita S, Kobayashi K, Nukiwa T, Takahashi K, North East Japan Study Group.
    Oncologist; 2018 Oct 02; 23(10):1210-1217. PubMed ID: 29567820
    [Abstract] [Full Text] [Related]

  • 18. A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21).
    Jung HA, Kim M, Kim HS, Kim JH, Choi YH, Cho J, Park JH, Park KU, Ku BM, Park S, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
    J Thorac Oncol; 2023 Feb 02; 18(2):223-231. PubMed ID: 36307042
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.
    Zucali PA, De Pas T, Palmieri G, Favaretto A, Chella A, Tiseo M, Caruso M, Simonelli M, Perrino M, De Vincenzo F, Toffalorio F, Damiano V, Pasello G, Garbella E, Ali M, Conforti F, Ottaviano M, Cioffi A, De Placido S, Giordano L, Bertossi M, Destro A, Di Tommaso L, Santoro A.
    J Clin Oncol; 2018 Feb 01; 36(4):342-349. PubMed ID: 29240542
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.